Study of gilteritinib for advanced ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an oral drug called gilteritinib for people with advanced ALK-positive non-small cell lung cancer that has progressed after prior ALK inhibitor treatment. It aims to see if gilteritinib can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced ALK-positive non-small cell lung cancer that cannot be cured with standard treatments.
- You must have had at least one prior ALK inhibitor therapy (like alectinib or lorlatinib) and your cancer has continued to grow.
- You need to be willing to provide a fresh tumor sample after your last cancer treatment, or if that's not possible, an older tumor sample.
- You should be able to perform daily activities with minor help (ECOG performance status 0-2).
- You must not be pregnant or breastfeeding, and agree to use effective contraception during and for a period after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called gilteritinib for people with a specific genetic type of lung cancer (ALK-positive) that has spread and has been treated before. You may be eligible if you have already tried at least one targeted therapy, and your cancer is still growing.
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
This trial tests a new combination of chemotherapy (FLAI) and a targeted drug (Gilteritinib) for adults with acute myeloid leukemia (AML) that has a specific genetic change called FLT3. It aims to see if the combo works better than standard treatment.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This trial studies the immune system's response when a drug called gilteritinib is given after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how gilteritinib affects your immune system and if it helps prevent the leukemia from coming back.
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.